Anti-B7-H3/CD276 Antibody (MirzotamAb)
Catalog No.
F1170
Anti-B7-H3/CD276 Antibody (MirzotamAb)
Featured Products
Mirzotamab is an IgG1κ monoclonal antibody targeting CD276/B7-H3 with anti-tumor activity. Mirzotamab can be combined with the BCL inhibitor Clezutoclax to form Mirzotamab clezutoclax, which can participate in taxane research on relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody-drug conjugate (ADC).
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
2229859-11-2
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Mirzotamab
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q5ZPR3
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
B7-H3 / CD276
Please avoid freeze-thaw cycles.